Locations:
Search
Phase 3 ODYSSEY-HCM trial of mavacamten leaves lingering questions about potential broader use
Tailored valve interventions prove effective for LVOTO without significant septal hypertrophy
5% of flagged ECGs in real-world study were from patients with previously undiagnosed HCM
High composite score in myectomy specimens signals worse prognosis
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Few patients report left ventricular dysfunction or heart failure after one year
Avoidance of septal reduction therapy continues while LVEF dysfunction remains infrequent
New risk score pools factors that may predict adverse outcomes in the uncommon phenotype
Serial strain assessments show sustained favorable impacts on LV systolic function and LA function
Large single-center series demonstrates safety and efficacy for extending procedure
JAMA study adds new data to decades-long guidance
Advertisement
Advertisement